Agna A Bartels-Velthuis1, Ellen Visser2, Johan Arends3, Gerdina H M Pijnenborg4, Lex Wunderink5, Frederike Jörg6, Wim Veling7, Edith J Liemburg8, Stynke Castelein9, Henderikus Knegtering10, Richard Bruggeman11. 1. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Hanzeplein 1 (CC72), 9713 GZ Groningen, The Netherlands; Lentis Mental Health Institution, Hereweg 80, 9725 AG Groningen, The Netherlands. Electronic address: a.a.bartels@umcg.nl. 2. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Hanzeplein 1 (CC72), 9713 GZ Groningen, The Netherlands. Electronic address: e.visser03@umcg.nl. 3. GGZ Drenthe, Mental Health Institution, Dennenweg 9, 9404 LA Assen, The Netherlands. Electronic address: johan.arends@ggzdrenthe.nl. 4. GGZ Drenthe, Mental Health Institution, Dennenweg 9, 9404 LA Assen, The Netherlands; University of Groningen, Faculty of Behavioural and Social Sciences, Department of Clinical Psychology & Experimental Psychopathology, Grote Kruisstraat 2/1, 9712 TS Groningen, The Netherlands. Electronic address: g.h.m.pijnenborg@rug.nl. 5. GGZ Friesland Mental Health Institution, Sixmastraat 2, 8932 PA Leeuwarden, The Netherlands. Electronic address: lex.wunderink@ggzfriesland.nl. 6. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Hanzeplein 1 (CC72), 9713 GZ Groningen, The Netherlands; GGZ Friesland Mental Health Institution, Sixmastraat 2, 8932 PA Leeuwarden, The Netherlands. Electronic address: f.jorg@umcg.nl. 7. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Psychosis Department, Hanzeplein 1 (CC60), 9713 GZ Groningen, The Netherlands. Electronic address: w.veling@umcg.nl. 8. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Hanzeplein 1 (CC72), 9713 GZ Groningen, The Netherlands. Electronic address: e.j.liemburg@umcg.nl. 9. Lentis Mental Health Institution, Hereweg 80, 9725 AG Groningen, The Netherlands. Electronic address: s.castelein@lentis.nl. 10. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Hanzeplein 1 (CC72), 9713 GZ Groningen, The Netherlands; Lentis Mental Health Institution, Hereweg 80, 9725 AG Groningen, The Netherlands. Electronic address: h.knegtering@lentis.nl. 11. University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Hanzeplein 1 (CC72), 9713 GZ Groningen, The Netherlands; University of Groningen, University Medical Center Groningen, Department of Pharmacy, Division of Pharmacotherapy and Pharmaceutical Care, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands. Electronic address: r.bruggeman@umcg.nl.
Abstract
BACKGROUND: Patients with psychotic disorders are at risk of developing mental health and social problems, and physical disorders. To monitor and treat these problems when indicated, an annual routine outcome monitoring program, Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS), was developed. This paper presents the background and content of PHAMOUS, implementation of PHAMOUS, characteristics of the patients screened in 2015, and the outcome of patients with three annual screenings between 2011 and 2015. METHODS: PHAMOUS was implemented in four mental health institutions in the Northern Netherlands in 2006. During the PHAMOUS screening, patients are assessed on socio-demographics, psychiatric symptoms, medication, physical parameters, lifestyle, (psycho)social functioning and quality of life, using internationally validated instruments. RESULTS: In 2015, 1955 patients with psychotic disorders were enrolled in the PHAMOUS screening. The majority (72%) was receiving mental healthcare for ten years or longer. A small group was hospitalized (10%) in the past year. Half of the patients were in symptomatic remission. Less than 10% had a paid job. More than half of the patients fulfilled the criteria for metabolic syndrome (54%). The subsample with three annual screenings from 2011 to 2015 (N = 1230) was stable, except the increasing prevalence of high glucose levels and satisfaction with social relationships (Cochran's Q = 16.33, p = .001 resp. Q = 14.79, p = .001). CONCLUSION: The annual PHAMOUS screening enables to follow the mental, physical and social health problems of patients, which offers a good basis for shared-decision making with regard to updating the annual treatment plan, next to a wealth of data for scientific research.
BACKGROUND:Patients with psychotic disorders are at risk of developing mental health and social problems, and physical disorders. To monitor and treat these problems when indicated, an annual routine outcome monitoring program, Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS), was developed. This paper presents the background and content of PHAMOUS, implementation of PHAMOUS, characteristics of the patients screened in 2015, and the outcome of patients with three annual screenings between 2011 and 2015. METHODS: PHAMOUS was implemented in four mental health institutions in the Northern Netherlands in 2006. During the PHAMOUS screening, patients are assessed on socio-demographics, psychiatric symptoms, medication, physical parameters, lifestyle, (psycho)social functioning and quality of life, using internationally validated instruments. RESULTS: In 2015, 1955 patients with psychotic disorders were enrolled in the PHAMOUS screening. The majority (72%) was receiving mental healthcare for ten years or longer. A small group was hospitalized (10%) in the past year. Half of the patients were in symptomatic remission. Less than 10% had a paid job. More than half of the patients fulfilled the criteria for metabolic syndrome (54%). The subsample with three annual screenings from 2011 to 2015 (N = 1230) was stable, except the increasing prevalence of high glucose levels and satisfaction with social relationships (Cochran's Q = 16.33, p = .001 resp. Q = 14.79, p = .001). CONCLUSION: The annual PHAMOUS screening enables to follow the mental, physical and social health problems of patients, which offers a good basis for shared-decision making with regard to updating the annual treatment plan, next to a wealth of data for scientific research.
Authors: Ji Chen; Kaustubh R Patil; Susanne Weis; Kang Sim; Thomas Nickl-Jockschat; Juan Zhou; André Aleman; Iris E Sommer; Edith J Liemburg; Felix Hoffstaedter; Ute Habel; Birgit Derntl; Xiaojin Liu; Jona M Fischer; Lydia Kogler; Christina Regenbogen; Vaibhav A Diwadkar; Jeffrey A Stanley; Valentin Riedl; Renaud Jardri; Oliver Gruber; Aristeidis Sotiras; Christos Davatzikos; Simon B Eickhoff Journal: Biol Psychiatry Date: 2019-09-23 Impact factor: 12.810
Authors: Anne Looijmans; Frederike Jörg; Richard Bruggeman; Robert A Schoevers; Eva Corpeleijn Journal: BMC Psychiatry Date: 2019-11-05 Impact factor: 3.630
Authors: E C D van der Stouwe; L A Steenhuis; G H M Pijnenborg; B de Vries; A A Bartels-Velthuis; S Castelein; W Veling; E Visser; J T van Busschbach Journal: BMC Psychiatry Date: 2021-11-01 Impact factor: 3.630